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Abstract 
Background: Multipotent mesenchymal stromal cells secretome contains a range of anti-inflammatory factors and can be 
used for the treatment of psoriasis. 
Material and Methods: The study included 16 male Wistar rats weighing from 214 to 256 g, which were divided into 2 
subgroups: 8 rats — positive control, treated with fluocinolone acetonide (―Sinaflan‖ 0.025% ointment, MPZ, Russia), 8 
rats - an experimental group that received a cream with a secret bone marrow MSC. Psoriasiform inflammation was caused 
by daily application of 50 μl of 1% imiquimod suspension (Xi'an Leader Biochemical Engineering Co., Ltd, China) on the 
skin of the back from the inner and outer surfaces in olive oil with DMSO in a ratio of 9:1 for 4 days. After the 
development of severe inflammation, treatment was started on both sides: on the one hand, each animal received a baby 
cream (negative control), on the other hand, fluocinolone or cream with the addition of MSC secretome in the 
corresponding group, application was carried out 1 time per day for 3 days. On the 8th day of the experiment, the animals 
were euthanized and skin fragments were collected for histological examination. 
Results and Discussion: On the day 4 of the imiquimod use, all animals showed the development of inflammation, with 
the appearance of coarse lamellae, excoriations, evenly on both sides in the application of the inducer of inflammation. The 
relief of inflammation as a result of daily single application of cream, cream with MSC secretion and fluocinolone was 
observed in the experimental group and in the positive control from the 2nd day of use, in the negative control on the 3rd 
day of the cream application the inflammation decreased slightly. 
Conclusion: The efficacy of topical administration of MSC secretome in relieving psoriasiform inflammation in Wistar 
rats is comparable to that of glucocorticoid with high activity (class 3 according to the European classification of Miller & 
Munro) fluorocinolone acetate, both by clinical signs and by morphometric indicators. 
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Background 
Psoriasis is a systemic disease with an unclear 
etiology and a well-studied pathogenesis. Preferably, 
the skin and joints are affected due to immuno-
inflammatory processes, where T-cell responses, 
especially Th17-mediated, which are known [1], play 
a key role in the pathogenesis of psoriasis. Traditional 
systemic therapy for psoriasis includes methotrexate, 
cyclosporine, acetretin, less commonly azathioprine, 
lefluenamide, sulfasalazine, and other 
immunosuppressants [2]. In recent years, antipsoriatic 
therapy has undergone changes, a large number of 
genetically engineered biological agents have 
appeared: anti-TNF-α - etanercept, infliximab and 
adalimumab, anti-IL12/IL23 p40 - ustekinumab, anti-
phosphodiesterase-4 - apremilast, anti-IL-17A - 
secukinumab, ixekizumab [3, 4]. All of them are 
aimed at blocking key mediators of immune 
inflammation after systemic administration. This 
approach is not selective and is also accompanied by 
undesirable side effects in the form of the 
development of general immunosuppression with an 
increase in infectious diseases. 
In topical preparations, the progress is much less, 
the main drugs, as before, remain glucocorticoids with 
known side effects, vitamin D analogues - calcipotriol 
(calcipotriene), retinoic acid derivative - tazarotene, 
birch tar, which have narrower indications [5, 6]. 
Thus, the problem of development new drugs for 
the treatment of psoriasis remains an actual task. 
Among promising candidates, we consider the 
secretome of multipotent mesenchymal stromal cells 
(MSCs). The anti-inflammatory and 
immunosuppressive effects of MSCs are known by 
inhibiting the activity of cytotoxic T-lymphocytes, 
dendritic cells, macrophages, stimulating regulatory T 
lymphocytes, with corresponding shifts in cytokine 
production [7, 8], including a decrease in Th17 
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differentiation and increased differentiation and 
activity of regulatory T-lymphocytes [9]. 
Preclinical research at the organismic [10-16], 
cellular [17] and subcellular levels [18, 19] with 
pathology modeling are a necessary for creating new 
drugs. The most popular vectors are the reduction of 
oxidative stress [20-23], inflammation [24, 25] and 
apoptosis cascades [26-29]. For the development of 
new drugs and therapies for any disease, it is desirable 
to have model laboratory animals of various kinds. 
Until recently, there were no relevant models of 
psoriasis at all: a xenotransplantation of psoriatic skin 
fragments from patients to mice with severe combined 
immunodeficiency mice (SCID) was used [30]. 
Despite the development of individual psoriasis-like 
skin changes in mice with various 
immunodeficiencies, these models were also not 
successful due to their insensitivity to standard anti-
psychotic therapy [31]. This led to the appearance of 
genetically modified mouse strains. Mice with an 
epidermis-specific deletion of the inhibitor of nuclear 
factor κB kinase 2 develop a T cell–independent 
psoriasis-like skin disease.  
The authors conclude that the critical function of 
nuclear factor κB kinase 2-mediated nuclear factor κB 
activity in keratinocytes is to regulate mechanisms 
that maintain the immune homeostasis of the skin 
[32], with overexpression of cytokines IL-6, TGF-α, 
IL-1α, IFN-γ, BMP-6, etc [33]. However, the features 
of these lines and the specific conditions of detention 
limit their availability to many researchers. Therefore, 
the development of a model of imiquimod-induced 
psoriasiform inflammation should be considered a 
significant step forward in the study of psoriasis and 
increasing the efficiency of developing new drugs for 
its treatment [34]. 
Imiquimod is a chemical TLR-7/8 agonist [35] and 
has been developed for the treatment of genital warts 
caused by human papillomavirus, senile keratosis and 
superficial basal cell carcinoma of the skin. One of the 
detected side effects was the development of a 
psoriasiform skin inflammation in the application area 
of a cream when applying 5% imiquimod cream [36-
39]. However, until recently, reproducible models of 
imiquimod-induced psoriasis were described in mice, 
both genetically modified, and later on the BALB/c 
and C57BL/6 lines.  
Recently, we have developed a model of 
imiquimod-induced psoriasiform inflammation in 
Wistar rats [40], which was used in the present study, 
the purpose of which was to study the effectiveness of 
the bone marrow MSCs secretome topical 
administration in arresting imiquimod-induced 
psoriasiform inflammation. 
 
Materials and Methods 
The study was conducted in accordance with the 
ethical standards, the declaration approved by the 
ethics committee. 
Mixing cream with secret MSC  
MSCs were obtained by washing out the bone 
marrow from the diaphysis of the femoral and tibial 
bones of Wistar rats, followed by rubbing it through a 
nylon membrane with pores of 100 μm, erythrocyte 
lysis with a buffer containing ammonium chloride, 
and cultivating people and laying themselves on 
DMEM medium (Paneco, Russia) 10% ETS (Biosera, 
France), antibiotics penicillin/streptomycin (Paneco, 
Russia) per 100 mm culture plates (Costar, USA) at 
37°C in a humid atmosphere with 5% CO2. After the 
formation of 90% of the MSC monolayer of the 4th-
5th passage, the medium on the plates was changed to 
10 ml of DMEM/F12 without serum and antibiotics. 
Cell cultivation was continued for 3 days, after which 
the supernatant was collected, dried on a rotavapor R-
300 rotary evaporator (Buchi, Switzerland) at 42°C. 
The dry residue was dissolved in 1/10 of the initial 
volume of distilled water and added to 9/10 of the 
initial volume of an indifferent cream (―Detskiy‖, 
Avanta, Russia), mixing thoroughly. Storage of the 
cream before use and during the experiment was 
carried out at + 4°C. 
Modeling and treatment of psoriasiform 
inflammation 
The study included 16 male Wistar rats weighing 
from 214 to 256 g, which were divided into 2 
subgroups: 8 rats — positive control, treated with 
fluocinolone acetonide (―Sinaflan‖ 0.025% ointment, 
MPZ, Russia), 8 rats - an experimental group that 
received a cream with a secret bone marrow MSC. 
Negative control as a cream treatment without the 
addition of MSC secretome, was performed in the 
same rats, on the contralateral side. Psoriasiform 
inflammation was caused by daily application of 50 μl 
of 1% imiquimod suspension (Xi'an Leader 
Biochemical Engineering Co., Ltd, China) to the ears 
from the inner and outer surfaces in olive oil with 
DMSO in a ratio of 9:1 for 4 days. 
After the development of severe inflammation, 
treatment was started on both sides: on the one hand, 
each animal received a baby cream (negative control), 
on the other hand, fluocinolone or cream with the 
addition of MSC secretome in the corresponding 
group, application was carried out 1 time per day for 3 
days. On the 8th day of the experiment, the animals 
were euthanized and skin fragments were collected for 
histological examination. Skin fragments were fixed 
with 4% formaldehyde, then stained with hematoxylin 
and eosin. Morphometric studies were performed on 
an AxioScope A1 (Zeiss) microscope in the Fiji [41] 
software package. Statistical processing was 
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performed in MS Excel 2013 with the Dunnet 
criterion. 
Results and Discussion 
On the day 4 of the imiquimod use, all animals 
showed the development of inflammation, with the 
appearance of coarse lamellae, excoriations, evenly on 
both sides in the application of the inducer of 
inflammation. The relief of inflammation as a result of 
daily single application of cream, cream with MSC 
secretion and fluocinolone was observed in the 
experimental group and in the positive control from 
the 2nd day of use, in the negative control on the 3rd 
day of the cream application the inflammation 
decreased slightly. 
The results of the histological study of autopsy 
material are presented in Figures 1-2. 
On the day 4 of the imiquimod use, all animals 
showed the development of inflammation, with the 
appearance of coarse lamellae, excoriations, evenly on 
both sides in the application of the inducer of 
inflammation. The relief of inflammation as a result of 
daily single application of cream, cream with MSC 
secretion and fluocinolone was observed in the 
experimental group and in the positive control from 
the 2nd day of use, in the negative control on the 3rd 
day of the cream application the inflammation 
decreased slightly. 
The results of the histological study of autopsy 
material are presented in Figures 1-2. 
 
Figure-1: Acanthosis severity: a - negative control, 
b - positive control (fluocinolone), c - experimental 
group (MSC secretome) 
 
Figure- 2: Hypertrophy of the capillaries in the 
dermis under the influence of imiquimod. 
As shown A.L. van der Fits et al. [31], imiquimod-
induced dermatitis was partially dependent on the 
presence of T-cells, while the development of the 
disease was almost completely blocked in mice 
deficient in IL-23 or IL-17 receptor, which 
demonstrates the key role of the IL-23/IL -17 axis. 
These lesions showed increased epidermal 
proliferation, abnormal differentiation, epidermal 
accumulation of neutrophils in microabscesses, 
neoangiogenesis and infiltrates consisting of CD4+ T 
cells, CD11c+ dendritic cells and plasmacytoid 
dendritic cells.  
Imiquimod induced epidermal expression of IL-23, 
IL-17A and IL-17F, as well as an increase in Th17 
spleen cells. As can be seen, the changes in BALB/c 
and C57BL/6 mice in this work and the identified skin 
changes in Wistar rats are very similar, which 
confirms the eligibility of using the latter in modeling 
psoriasiform inflammation under the influence of 
imiquimod [42]. 
Morphometric indicators are presented below on 
the fig. 3-5. 
 
Figure -3: Total cellularity of skin. * - p <0.05. 
 
Figure- 4: Derma thickness. * - p <0.05. 
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Figure -5: Acanthosis severity. * - p <0.05. 
The efficacy of topical administration of MSC 
secretome in relieving psoriasiform inflammation in 
Wistar rats is comparable to that of glucocorticoid 
with high activity (class 3 according to the European 
classification of Miller & Munro) fluorocinolone 
acetate, both by clinical signs and by morphometric 
indicators. So, the total cellularity of the specimens in 
the negative control was 876.9±77.5 (M±sd), in the 
positive control – 572.8±75.4, and in the experimental 
group – 589.4±105.4. The thickness of the dermis in 
microns in the control is 893.0±71.1, with the use of 
fluocinolone acetate – 607.8±83.7, and in the case of 
using the secretome of MSC – 629.1±48.0. Also, 
under the influence of factors produced by MSCs, the 
following characteristic for psoriatic skin lesions 
decreased statistically significantly: acanthosis – 
253.6±35.9 µm, against 252.0±54.8 µm under the 
influence of fluocinolone acetate and 677.1±80.6 
microns in the negative control. 
Thus, the anti-inflammatory and 
immunosuppressive activity of the complex of 
humoral factors constituting the secret of MSCs 
provided relief for acute psoriasiform skin 
inflammation and showed potential for further in-
depth experimental research in the treatment of Th17-
dependent inflammation. 
The obtained experimental data require further 
research in the direction of establishing cellular 
targets for the components of the MSC secretome in 
psoriasiform inflammation induced by imiquimod, 
since Th17 are not the only participants in this 
process. In [43], direct evidence is presented for the 
ability of the innate immune system to "control" 
psoriasis through TLR7 (agonist receptor 7) 
imiquimod. Induction of pronounced type 1 interferon 
activity in the lesion focus and the discovery of a 
large number of precursors of dendritic cells initiating 
psoriatic skin lesions suggest that the precursors of 
dendritic cells may be targets for a TLR7 imiquimod 
agonist for psoriasis. Whether precursors of dendritic 
cells represent key cellular mediators of innate 
immune responses that cause pathogenic events 
leading to psoriasis will need to be determined in 
future studies. 
There are numerous works suggested that MSCs 
inhibit the proliferation of human and animal T cells 
stimulated with polyclonal mitogens, allogeneic cells, 
soluble antigens, anti-CD3 and anti-CD38 antibodies 
[44-46], which requires further experiments to clarify 
how biologically active factors presented in the 
secretome of MSCs suppress imiquimod-induced skin 
inflammation. 
The efficacy of topical administration of MSC 
secretome in relieving psoriasiform inflammation in 
Wistar rats is comparable to that of glucocorticoid 
with high activity (class 3 according to the European 
classification of Miller & Munro) fluorocinolone 
acetate, both by clinical signs and by morphometric 
indicators. So, the total cellularity of the specimens in 
the negative control was 876.9±77.5 (M±sd), in the 
positive control – 572.8±75.4, and in the experimental 
group – 589.4±105.4. The thickness of the dermis in 
microns in the control is 893.0±71.1, with the use of 
fluocinolone acetate ¬– 607.8±83.7, and in the case of 
using the secretome of MSC – 629.1±48.0. Also, 
under the influence of factors produced by MSCs, the 
following characteristic for psoriatic skin lesions 
decreased statistically significantly: acanthosis – 
253.6±35.9 µm, against 252.0±54.8 µm under the 
influence of fluocinolone acetate and 677.1±80.6 
microns in the negative control. 
Conclusion 
Thus, the anti-inflammatory and 
immunosuppressive activity of the complex of 
humoral factors constituting the secret of MSCs 
provided relief for acute psoriasiform skin 
inflammation and showed potential for further in-
depth experimental research in the treatment of Th17-
dependent inflammation. 
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